Results 11 to 20 of about 464,133 (328)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1

Frontiers in Pharmacology, 2022
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, driven by the BCR-ABL1 fusion oncoprotein. The discovery of orthosteric BCR-ABL1 tyrosine kinase inhibitors (TKIs) targeting its active ATP-binding pocket, such as first-generation Imatinib
Hao Zhang, Hao Zhang, Mingsheng Zhu, Mingzi Li, Duan Ni, Yuanhao Wang, Liping Deng, Kui Du, Shaoyong Lu, Hui Shi, Chen Cai   +10 more
doaj   +2 more sources

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma

Frontiers in Oncology, 2023
Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are ...
Antoine Domenger, Daniela Ricci, Véronique Mayau, Laleh Majlessi, Christophe Marcireau, Gilles Dadaglio, Caroline Demangel   +6 more
doaj   +2 more sources

Nude mice multi-drug resistance model of orthotopic transplantation of liver neoplasm and Tc-99m MIBI SPECT on p-glycoprotein

World Journal of Gastroenterology, 2005
To establish a model of drug-resistant neoplasms using a nude mice model, orthotopic transplantation of liver neoplasm and sporadic abdominal chemotherapy.Hepatocellular carcinoma cells HepG2 were cultured and injected subdermally to form the tumor-supplying mice.
Zhi-Yong Huang, Hong Zhu, Yu Han, Xiaoping Chen   +3 more
openaire   +4 more sources

PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib

Frontiers in Oncology, 2021
Multiple myeloma (MM), the second most commonly diagnosed hematologic neoplasm, is the most significant clinical manifestation in a series of plasma cell (PC) dyscrasia.
Dong Wu, Jiyu Miao, Jinsong Hu, Fangmei Li, Dandan Gao, Hongli Chen, Yuandong Feng, Ying Shen, Aili He   +8 more
doaj   +2 more sources

Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma
Xiaoju Huang,1– 3 Mengmeng Wang,1– 3 Dan Zhang,1– 3 Chen Zhang,4 Pian Liu1– 3 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China; 2Institute of Radiation ...
Huang X, Wang M, Zhang D, Zhang C, Liu P
doaj   +2 more sources

Drug resistance biomarkers in ovarian cancer: a bibliometric study from 2017 to 2022 [PDF]

Frontiers in Oncology
BackgroundLate diagnosis and patient relapse, mainly due to chemoresistance, are the key reasons for the high mortality rate of ovarian cancer patients. Hence, the search for biomarkers of high predictive value within the phenomenon of chemoresistance is
Sindy Cabarca, Sindy Cabarca, Carmen Ili, Carlos Vanegas, Laura Gil, Laura Gil, Melba Vertel-Morrinson, Melba Vertel-Morrinson, Priscilla Brebi   +8 more
doaj   +2 more sources

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review) [PDF]

International Journal of Oncology, 2016
Multiple myeloma (MM) is a mature B cell neoplasm that results in multi-organ failure. The median age of onset, diverse clinical manifestations, heterogeneous survival rate, clonal evolution, intrinsic and acquired drug resistance have impact on the ...
Bebawy, M, Brown, RD, Jaiswal, R, Krishnan, SR, Luk, F   +4 more
core   +2 more sources

KDM4C contributes to cytarabine resistance in acute myeloid leukemia regulating the miR-328-3p/CCND2 axis through MALAT1

Therapeutic Advances in Chronic Disease, 2021
Aims: Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm, in which relapse due to drug resistance is the main cause for treatment failure and the disease progression. In this study, we aimed to investigate the molecular mechanism of KDM4C-
Lu Xue, Chunhuai Li, Jin Ren, Yue Wang
doaj   +2 more sources

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Experimental Hematology & Oncology, 2020
Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1.
Theresa Klümper, Henrike Bruckmueller, Tobias Diewock, Meike Kaehler, Sierk Haenisch, Christiane Pott, Oliver Bruhn, Ingolf Cascorbi   +7 more
doaj   +2 more sources

Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients [PDF]

Iranian Journal of Medical Sciences, 2023
Background: Circulating microRNAs (miRNAs) can help to predict the chemotherapy response in breast cancer with promising results. The aim of the present study was to investigate the relationships between the miR-199a, miR-663a, and miR-663b expression ...
Mehdi Dehghani, Samira Mokhtari, Hassan Abidi, Behnam Alipoor, Mohammad Amin Nazer Mozaffari, Hossein Sadeghi, Reza Mahmoudi, Mohsen Nikseresht   +7 more
doaj   +1 more source